JP2024522183A - 非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 - Google Patents
非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 Download PDFInfo
- Publication number
- JP2024522183A JP2024522183A JP2023575827A JP2023575827A JP2024522183A JP 2024522183 A JP2024522183 A JP 2024522183A JP 2023575827 A JP2023575827 A JP 2023575827A JP 2023575827 A JP2023575827 A JP 2023575827A JP 2024522183 A JP2024522183 A JP 2024522183A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methoxyphenyl
- pyridazin
- oxadiazol
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208918P | 2021-06-09 | 2021-06-09 | |
| US63/208,918 | 2021-06-09 | ||
| PCT/US2022/032798 WO2022261296A1 (en) | 2021-06-09 | 2022-06-09 | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522183A true JP2024522183A (ja) | 2024-06-11 |
| JP2024522183A5 JP2024522183A5 (OSRAM) | 2025-06-18 |
Family
ID=82492690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575827A Pending JP2024522183A (ja) | 2021-06-09 | 2022-06-09 | 非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240287054A1 (OSRAM) |
| EP (1) | EP4352054A1 (OSRAM) |
| JP (1) | JP2024522183A (OSRAM) |
| AU (1) | AU2022288631A1 (OSRAM) |
| CA (1) | CA3222837A1 (OSRAM) |
| WO (1) | WO2022261296A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025184571A1 (en) * | 2024-03-01 | 2025-09-04 | City Of Hope | Pcna inhibitors for the treatment of myc family associated cancers |
| GB202414343D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
| GB202414345D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
| GB202414337D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| AU2009253046A1 (en) * | 2008-05-30 | 2009-12-03 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| US10463649B2 (en) * | 2015-06-08 | 2019-11-05 | Texas Tech University System | Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors |
-
2022
- 2022-06-09 WO PCT/US2022/032798 patent/WO2022261296A1/en not_active Ceased
- 2022-06-09 US US18/568,738 patent/US20240287054A1/en active Pending
- 2022-06-09 AU AU2022288631A patent/AU2022288631A1/en active Pending
- 2022-06-09 JP JP2023575827A patent/JP2024522183A/ja active Pending
- 2022-06-09 EP EP22741091.7A patent/EP4352054A1/en active Pending
- 2022-06-09 CA CA3222837A patent/CA3222837A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3222837A1 (en) | 2022-12-15 |
| US20240287054A1 (en) | 2024-08-29 |
| AU2022288631A1 (en) | 2024-01-18 |
| WO2022261296A1 (en) | 2022-12-15 |
| EP4352054A1 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6849711B2 (ja) | Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤 | |
| US20240287054A1 (en) | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same | |
| JP2026004408A (ja) | 抗体ｐｒｏｔａｃコンジュゲート | |
| JP6789239B2 (ja) | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 | |
| US20260085058A1 (en) | Degraders of son of sevenless homolog 1 | |
| KR20210045998A (ko) | 헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법 | |
| CN111032662A (zh) | 与ras超家族相互作用的用于治疗癌症、炎性疾病、ras蛋白病和纤维化疾病的化合物 | |
| KR20200010306A (ko) | Kras의 공유적 억제제 | |
| US11014902B2 (en) | MYC G-quadruplex stabilizing small molecules and their use | |
| JP2024529976A (ja) | がんを治療する方法 | |
| JP2021506973A (ja) | がん治療のための１−（ピペリジノカルボニルメチル）−２−オキソピペラジン誘導体 | |
| JP7850460B2 (ja) | ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用 | |
| JP2023095928A (ja) | 癌を処置するためのｅｚｈ２阻害剤の使用 | |
| CN118234497A (zh) | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) | |
| JP2019508496A (ja) | 癌の治療法のためのｔａｆ１阻害剤 | |
| CN106456616A (zh) | 小分子C‑Myc抑制剂 | |
| Hu et al. | Discovery of highly potent and efficient CBP/p300 degraders with strong in vivo antitumor activity | |
| CN111432820A (zh) | 异染色质基因阻抑抑制剂 | |
| US9216177B2 (en) | Small molecular inhibitors of RAD51 recombinase and methods thereof | |
| JP2022526844A (ja) | 筋肉量及び酸化的代謝を増加させるための組成物及び方法 | |
| WO2023203172A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| CN118043053A (zh) | 治疗癌症的方法 | |
| TW202328137A (zh) | 用於治療無關ｍｍｒ狀態之ｍｇｍｔ欠缺性癌症的化合物及方法 | |
| TW202438056A (zh) | 雜環化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250609 |